216 related articles for article (PubMed ID: 15058791)
21. Cyclosporin versus etretinate: Italian multicenter comparative trial in severe plaque-form psoriasis. Italian Multicenter Study Group on Cyclosporin in Psoriasis.
Dermatology; 1993; 187 Suppl 1():8-18. PubMed ID: 8369579
[TBL] [Abstract][Full Text] [Related]
22. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
Bruins FM; Bronckers IMGJ; Groenewoud HMM; van de Kerkhof PCM; de Jong EMGJ; Seyger MMB
JAMA Dermatol; 2020 Jan; 156(1):72-78. PubMed ID: 31774449
[TBL] [Abstract][Full Text] [Related]
23. Low-dose, short-term ciclosporin (Neoral®) therapy is effective in improving patients' quality of life as assessed by Skindex-16 and GHQ-28 in mild to severe psoriasis patients.
Okubo Y; Natsume S; Usui K; Amaya M; Tsuboi R
J Dermatol; 2011 May; 38(5):465-72. PubMed ID: 21352289
[TBL] [Abstract][Full Text] [Related]
24. ISA247: quality of life results from a phase II, randomized, placebo-controlled study.
Gupta AK; Langley RG; Lynde C; Barber K; Gulliver W; Lauzon G; Aspeslet LJ; Foster RT; Huizinga RB; Yatscoff RW
J Cutan Med Surg; 2008; 12(6):268-75. PubMed ID: 19317948
[TBL] [Abstract][Full Text] [Related]
25. Low-dose (1.25 mg/kg) cyclosporin A: treatment of psoriasis and investigation of the influence on lipid profile.
Meffert H; Bräutigam M; Färber L; Weidinger G
Acta Derm Venereol; 1997 Mar; 77(2):137-41. PubMed ID: 9111826
[TBL] [Abstract][Full Text] [Related]
26. A prospective, interventional assessment of psoriasis quality of life using a nonskin-specific validated instrument that allows comparison with other major medical conditions.
Bhutani T; Patel T; Koo B; Nguyen T; Hong J; Koo J
J Am Acad Dermatol; 2013 Aug; 69(2):e79-88. PubMed ID: 23207011
[TBL] [Abstract][Full Text] [Related]
27. Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR; Gordon KB; Bala M; Evans R; Li S; Dooley LT; Guzzo C; Patel K; Menter A; Gottlieb AB
Br J Dermatol; 2005 May; 152(5):954-60. PubMed ID: 15888152
[TBL] [Abstract][Full Text] [Related]
28. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group.
Koo J
Br J Dermatol; 1998 Jul; 139(1):88-95. PubMed ID: 9764154
[TBL] [Abstract][Full Text] [Related]
29. Clinical aspects: preliminary experience with a novel oral formulation of cyclosporin (Neoral).
Berth-Jones J
Br J Dermatol; 1996 Sep; 135 Suppl 48():5-8. PubMed ID: 8881897
[TBL] [Abstract][Full Text] [Related]
30. Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study.
Thaçi D; Bräutigam M; Kaufmann R; Weidinger G; Paul C; Christophers E
Dermatology; 2002; 205(4):383-8. PubMed ID: 12444336
[TBL] [Abstract][Full Text] [Related]
31. A comparison of mycophenolate mofetil with ciclosporine for the treatment of chronic plaque-type psoriasis.
Beissert S; Pauser S; Sticherling M; Frieling U; Loske KD; Frosch PJ; Haase I; Luger TA
Dermatology; 2009; 219(2):126-32. PubMed ID: 19546522
[TBL] [Abstract][Full Text] [Related]
32. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis.
Maza A; Montaudié H; Sbidian E; Gallini A; Aractingi S; Aubin F; Bachelez H; Cribier B; Joly P; Jullien D; Le Maître M; Misery L; Richard MA; Ortonne JP; Paul C
J Eur Acad Dermatol Venereol; 2011 May; 25 Suppl 2():19-27. PubMed ID: 21388455
[TBL] [Abstract][Full Text] [Related]
33. The cost effectiveness of tapered versus abrupt discontinuation of oral cyclosporin microemulsion for the treatment of psoriasis.
Hakkaart-van Roijen L; Verboom P; Redekop WK; Touw KR; Rutten FF
Pharmacoeconomics; 2001; 19(5 Pt 2):599-608. PubMed ID: 11465304
[TBL] [Abstract][Full Text] [Related]
34. The Impact of Changes in Psoriasis Area and Severity Index by Body Region on Quality of Life in Patients with Psoriasis.
Sojević Timotijević Z; Majcan P; Trajković G; Relić M; Novaković T; Mirković M; Djurić S; Nikolić S; Lazić B; Janković S
Acta Dermatovenerol Croat; 2017 Oct; 25(3):215-222. PubMed ID: 29252174
[TBL] [Abstract][Full Text] [Related]
35. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis.
Heydendael VM; Spuls PI; Opmeer BC; de Borgie CA; Reitsma JB; Goldschmidt WF; Bossuyt PM; Bos JD; de Rie MA
N Engl J Med; 2003 Aug; 349(7):658-65. PubMed ID: 12917302
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
37. Medication formulation affects quality of life: a randomized single-blind study of clobetasol propionate foam 0.05% compared with a combined program of clobetasol cream 0.05% and solution 0.05% for the treatment of psoriasis.
Bergstrom KG; Arambula K; Kimball AB
Cutis; 2003 Nov; 72(5):407-11. PubMed ID: 14655784
[TBL] [Abstract][Full Text] [Related]
38. Long-term continuous versus intermittent cyclosporin: therapy for psoriasis.
Ohtsuki M; Nakagawa H; Sugai J; Ozawa A; Ohkido M; Nakayama J; Hanada J; Morimoto Y; Jimbow K; Horikoshi T; Kitahara H; Tamaki K; Urabe K; Hori Y
J Dermatol; 2003 Apr; 30(4):290-8. PubMed ID: 12707465
[TBL] [Abstract][Full Text] [Related]
39. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.
Reich K; Nestle FO; Papp K; Ortonne JP; Wu Y; Bala M; Evans R; Guzzo C; Li S; Dooley LT; Griffiths CE
Br J Dermatol; 2006 Jun; 154(6):1161-8. PubMed ID: 16704649
[TBL] [Abstract][Full Text] [Related]
40. Short- and long-term considerations concerning the management of plaque psoriasis with low-dose cyclosporin. Studio Italiano Multicentrico nella Psoriasi (SIMPSO).
Dermatology; 1993; 187 Suppl 1():19-29. PubMed ID: 8369576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
